10.3389/fphar.2018.00700.s001
Chiyuan Ma
Chiyuan
Ma
Xiaopeng Zhou
Xiaopeng
Zhou
Kai Xu
Kai
Xu
Linyan Wang
Linyan
Wang
Yute Yang
Yute
Yang
Wei Wang
Wei
Wang
An Liu
An
Liu
Jisheng Ran
Jisheng
Ran
Shigui Yan
Shigui
Yan
Haobo Wu
Haobo
Wu
Lidong Wu
Lidong
Wu
Data_Sheet_1_Specnuezhenide Decreases Interleukin-1β-Induced Inflammation in Rat Chondrocytes and Reduces Joint Destruction in Osteoarthritic Rats.DOCX
Frontiers
2018
specnuezhenide
osteoarthritis
chondrocyte
NF-κB
wnt/β-catenin
2018-06-28 14:06:51
Dataset
https://frontiersin.figshare.com/articles/dataset/Data_Sheet_1_Specnuezhenide_Decreases_Interleukin-1_-Induced_Inflammation_in_Rat_Chondrocytes_and_Reduces_Joint_Destruction_in_Osteoarthritic_Rats_DOCX/6715649
<p>As a chronic disease, osteoarthritis (OA) leads to the degradation of both cartilage and subchondral bone, its development being mediated by proinflammatory cytokines like interleukin-1β. In the present study, the anti-inflammatory effect of specnuezhenide (SPN) in OA and its underlying mechanism were studied in vitro and in vivo. The results showed that SPN decreases the expression of cartilage matrix-degrading enzymes and the activation of NF-κB and wnt/β-catenin signaling, and increases chondrocyte-specific gene expression in IL-1β-induced inflammation in chondrocytes. Furthermore, SPN treatment prevents the degeneration of both cartilage and subchondral bone in a rat model of OA. To the best of our knowledge, this study is the first to report that SPN decreases interleukin-1β-induced inflammation in rat chondrocytes by inhibiting the activation of the NF-κB and wnt/β-catenin pathways, and, thus, has therapeutic potential in the treatment of OA.</p>